Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry [5]. Core Viewpoints - The investment enthusiasm for innovative drugs remains high, with a focus on genuine innovation and stable high-dividend stocks. The recent ASCO annual meeting showcased the competitiveness of Chinese pharmaceutical companies in new drug development, leading to a positive market response [2][23]. - The report suggests focusing on companies with strong clinical progress and international expansion capabilities, such as Yifang Biotech-U, Zai Lab-U, Rongchang Biotech (A+H), and Xinlitai [2][24]. - Given the complex macroeconomic environment and recent financial policies aimed at stabilizing the market, leading pharmaceutical companies with robust growth and high dividend characteristics are seen as attractive investment opportunities [2][24]. Summary by Sections Market Review - Last week, the pharmaceutical and biotechnology index rose by 1.13%, outperforming the CSI 300 index by 0.25 percentage points but underperforming the ChiNext index by 1.53 percentage points, ranking 17th among 31 sub-industries [1][18]. - The Hong Kong Hang Seng Healthcare Index increased by 6.1%, outperforming the Hang Seng China Enterprises Index by 3.76 percentage points [1][18]. Company Updates - Recent developments include the IND application for HRS-4508 by Heng Rui Pharmaceutical and ongoing clinical trials for HMPL-306 and HS-10374 by Hutchison China MediTech, as well as HS-10506 and CM518D1 by Hansoh Pharmaceutical and ConvaTec, respectively [32][34]. High Dividend Stocks - The report identifies several high-dividend stocks in the pharmaceutical sector, including Huate Dain, Jichuan Pharmaceutical, Kefu Medical, Xizang Pharmaceutical, Jiangzhong Pharmaceutical, and others, which are expected to benefit from recent monetary and fiscal policies [2][24][25]. R&D Progress - The report highlights the ongoing clinical trials and regulatory approvals for various innovative drugs, indicating a robust pipeline for the companies involved [32][34]. Investment Strategy - The report emphasizes a structural selection of investment opportunities based on payment willingness and ability, focusing on three payment channels: hospital payments, out-of-pocket payments, and overseas payments. Key recommendations include Heng Rui Pharmaceutical, Mindray Medical, United Imaging Healthcare, and Yiyuan Medical [29].